Skip to main content

Advertisement

SpringerLink
Log in

The Early Engagement Model in Product Development: Linking “Proof of Concept” to “Proof of Medical Value”

  • Product Development and Innovation: Analytical Report
  • Published:
Therapeutic Innovation & Regulatory Science Aims and scope Submit manuscript

Abstract

In a rapidly changing health care environment, it is more important than ever that pharmaceutical manufacturers improve the quality and efficiency of their research and development efforts in order to help ensure the right drug gets to the right patient at the right time. The evolving role of the Medical Affairs, Health Economics & Outcomes Research (HEOR) and other functions engaged in evidence generation within the pharmaceutical industry is leading to earlier involvement in the clinical development process so that the proof of concept for new therapies can be more strongly linked to the proof of medical value. In this article, the authors outline key components of an Early Engagement Model that connects the proof of concept to proof of medical value through a systematic approach linking molecular profile with early insights on disease, unmet needs, stakeholder requirements, and patient-centric differentiation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Centers for Medicare & Medicaid Services (CMS). Improving quality of care for Medicare Patients: accountable care organizations. Publication ICN 907407. Medicare Learning Network April 2014; https://www.cms.gov/medicare/medicare-fee-for-service-payment/sharedsavingsprogram/downloads/aco_quality_factsheet_icn907407.pdf. Accessed September 14, 2015.

  2. The Wall Street Journal. ObamaCare’s Failing Cost Control: The law’s “accountable care” experiment is a bust so far. The Wall Street Journal, October 20, 2014. http://www.wsj.com/articles/obamacares-failing-cost-control-1413758684. Accessed September 14, 2015.

  3. Weisman R. Cystic fibrosis doctors challenge Vertex over high price of new drug. The Boston Globe July 20, 2015. https://www.bostonglobe.com/business/2015/07/20/researcher-and-group-doctors-challenge-vertex-price-new-cystic-fibrosis-drug/d5PZMlj6T6uzq0usm2xLEL/story.html. Accessed September 14, 2015.

  4. Whalen J. Doctors object to high cancer-drug prices: more than 100 oncologists call for new regulations to control soaring patient costs in US. The Wall Street Journal July 23, 2015. http://www.wsj.com/articles/doctors-object-to-high-cancer-drug-prices-1437624060. Accessed September 14, 2015.

  5. Critical Path Institute, Tucson, AZ. http://c-path.org. Accessed October 26, 2015.

  6. Patient-Centered Outcomes Research Institute. Washington, DC. http://www.pcori.org/. Accessed October 26, 2015.

  7. MEDI8897 receives fast track designation by the FDA for the prevention of respiratory disease caused by RSV in infants. Fierce Vaccines, Info From Business Wire, Gaithersburg, MD, April 13, 2015. http://www.fiercevaccines.com/press-releases/medi8897-receives-fast-track-designation-fda-prevention-respiratory-disease. Accessed September 14, 2015.

  8. Genzyme Corporation. FDA grants fast track designation to Genzyme’s investigational substrate reduction therapy for the treatment of Fabry disease. Press release. Cambridge, MA. April 28, 2015. http://news.genzyme.com/press-release/fda-grants-fast-track-designation-genzymes-investigational-substrate-reduction-therapy. Accessed September 14, 2015.

  9. Center for Biologics Evaluation and Research, Center for Drug Evaluation and Research, US Food and Drug Administration, US Department of Health and Human Services. Guidance for Industry. Expedited programs for serious conditions—drugs and biologics. OMB Control No. 0910-0765. Expiration Date: 03/31/2017. May 2014. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm358301.pdf. Accessed September 14, 2015.

  10. US Food and Drug Administration. Accelerated approvals. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/NDAandBLAApprovalReports/ucm373430.htm. Accessed September 14, 2015.

  11. US Food and Drug Administration. Breakthrough therapy approvals. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/NDAandBLAApprovalReports/ucm373418.htm. Accessed September 14, 2015.

  12. Smith BL, Breitfeld PP. Optimizing oncology clinical trials with personalized medicine. December 30, 2013. http://www.dddmag.com/articles/2013/12/optimizing-oncology-clinical-trials-personalized-medicine. Accessed September 14, 2015.

  13. Syed S. Personalized medicine for “niche” populations. February 1, 2013. https://www.telushealth.co/item/companion-tests-safe-effective/. Accessed September 14, 2015.

  14. Kassenärztliche Bundesvereinigung. Extract of Cannabis sativa. July 21, 2012; http://www.kbv.de/html/8877.php. Accessed September 14, 2015.

  15. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte—Nr. 272: Ibrutinib—Bewertung gemäß § 35a Abs. 1 Satz 10 SGB V. https://www.iqwig.de/download/G14-11_Ibrutinib_Bewertung-35a-Abs-1-Satz10-SGB-V.pdf. Accessed September 15, 2015.

  16. Cann K, Karia R, Plested M, Samuels E. A comparison of reasons for recommendation and rejection in four health technology appraisal systems: NICE, SMC, CADTH, and PBAC. Abstract of Presentation HT3 at ISPOR 11th Annual European Congress, November 8-11, 2008, Athens, Greece. Value Health. 2008;11(6):338.

    Article  Google Scholar 

  17. Salimi T, Lehner JP, Epstein RS, Tunis SR. A framework for pharmaceutical value-based innovations. J Comp Eff Res. 2012;1(1 suppl):3–7.

    Article  Google Scholar 

  18. Tunis SR. Lack of evidence for clinical and health policy decisions. BMJ. 2013;347:f7155.

    Article  Google Scholar 

  19. IMS Consulting Group, Gupta M, Seiter S, Von Allmen H, Jaffe H. A new foundation for designing winning brand strategies: the patient journey re-envisioned. https://www.imshealth.com/deployedfiles/imshealth/Global/Content/Healthcare/Life%20Sciences%20Solutions/Pharmaceutical_Commercial/IMSCG_Patient%20_Journey_whitepaper.pdf. Accessed October 26, 2015.

  20. Policy and Medicine. Compliance challenges within medical affairs. http://www.policymed.com/2014/06/compliance-challenges-within-medical-affairs.html. Accessed September 14, 2015.

  21. Center for Biologics Evaluation and Research, Center for Drug Evaluation and Research, US Food and Drug Administration, US Department of Health and Human Services. Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. December 2009. http://www.fda.gov/downloads/Drugs/…/Guidances/UCM193282.pdf. Accessed September 14, 2015.

  22. Evers M, Fleming E, Ghatak A, et al. Pharma Medical Affairs 2020 and beyond. http://www.mckinsey.com/∼/media/mckinsey/dotcom/client_service/pharma%20and%20medical%20products/pmp%20new/pdfs/pharma_medical_affairs_2020.ashx. Accessed September 14, 2015.

Download references

Author information

Authors and Affiliations

  1. Global Medical Affairs, AstraZeneca, 141 Portland Street, Cambridge, MA, 02139, USA

    Sheikh Usman Iqbal MD, MPH, MBA & Tehseen Salimi MD

  2. Neuroscience Innovative Medicines, AstraZeneca, Cambridge, MA, USA

    John Dunlop PhD

  3. Evidera, Lexington, MA, USA

    L. Clark Paramore MSPH

Authors
  1. Sheikh Usman Iqbal MD, MPH, MBA
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tehseen Salimi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. John Dunlop PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L. Clark Paramore MSPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sheikh Usman Iqbal MD, MPH, MBA.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Iqbal, S.U., Salimi, T., Dunlop, J. et al. The Early Engagement Model in Product Development: Linking “Proof of Concept” to “Proof of Medical Value”. Ther Innov Regul Sci 50, 592–601 (2016). https://doi.org/10.1177/2168479016642816

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1177/2168479016642816

Keywords

Search

Navigation